Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial symbols : Abbv save search
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.75%
H: 0.0%
C: 0.0%
rinvoq positive cell results study
Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303
Published: 2024-03-05 (Crawled : 12:00) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.24%
H: 0.0%
C: 0.0%
df4101 dragonfly first abbvie payment trial milestone
Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3
Published: 2024-01-08 (Crawled : 13:00) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.52%
H: 0.0%
C: 0.0%
positive program trial results
AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC)
Published: 2023-11-29 (Crawled : 14:30) - biospace.com/
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.73%
H: 0.78%
C: 0.35%
lung abbvie positive cancer cell topline trial results
Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti-CD39 Antibody, in First Line Metastatic Pancreatic Cancer Patients
Published: 2023-11-09 (Crawled : 14:00) - biospace.com/
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -1.81%
H: 0.43%
C: -2.1%
ttx-030 cancer pancreatic trial therapeutics phase 2
Lupus Therapeutics Partners with AbbVie on Clinical Trial Recruitment Efforts in SLE Through LuCIN Lupus Clinical Trial Network
Published: 2023-10-24 (Crawled : 13:30) - biospace.com/
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.3%
H: 0.0%
C: 0.0%
abbvie lupus network trial therapeutics
AbbVie Announces Upadacitinib (RINVOQ®) Met the Primary Endpoint in Phase 2 Clinical Trial of Vitiligo as Program Advances to Phase 3
Published: 2023-10-12 (Crawled : 11:00) - biospace.com/
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.65%
H: 0.0%
C: 0.0%
rinvoq abbvie program trial
AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic Dermatitis
Published: 2023-10-11 (Crawled : 13:00) - biospace.com/
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.08%
H: 0.0%
C: 0.0%
abbvie dermatitis rinvoq
Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimer’s Disease
Published: 2023-09-07 (Crawled : 11:00) - globenewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.13%
H: 1.95%
C: 1.89%
ALEC | $5.27 -1.31% -1.33% 380K
|
Health Technology
|
| O: -1.24%
H: 10.79%
C: 8.09%
al002 disease alzheimer’s trial
Journal of Cosmetic Dermatology Publishes Data Demonstrating Patient Satisfaction with Natural-Looking Outcomes Following Treatment with OnabotulinumtoxinA (BOTOX® Cosmetic)
Published: 2023-08-30 (Crawled : 15:00) - biospace.com/
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
botox treatment
AbbVie Advances Immunology Pipeline with First Patient Dosed in Global Phase 3 Trial of Upadacitinib (RINVOQ®) in Hidradenitis Suppurativa
Published: 2023-07-24 (Crawled : 12:00) - prnewswire.com
UBS | News J | $27.36 -3.63% 0.0% 3.2M
|
Finance
|
| O: 0.85%
H: 0.33%
C: -0.23%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.48%
H: 0.0%
C: 0.0%
rinvoq abbvie pipeline global immunology trial
AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Published: 2023-06-27 (Crawled : 23:00) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.0%
H: 0.43%
C: -0.07%
GMAB | News | $28.47 -0.32% -0.32% 460K
|
Health Technology
|
| O: -1.28%
H: 0.97%
C: 0.86%
cd20 duobody abbvie positive topline trial results
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Published: 2023-06-27 (Crawled : 23:00) - globenewswire.com
GNMSF | News | $290.34 3.83% 340
|
Health Technology
|
| O: 0.91%
H: 0.0%
C: -1.43%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.0%
H: 0.43%
C: -0.07%
GMAB | News | $28.47 -0.32% -0.32% 460K
|
Health Technology
|
| O: -1.28%
H: 0.97%
C: 0.86%
cd20 duobody abbvie positive topline trial results
Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
Published: 2023-06-05 (Crawled : 22:00) - globenewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.45%
H: 0.05%
C: -1.48%
CHRS | $2.03 -6.88% -7.39% 720K
|
Health Technology
|
| O: 0.4%
H: 9.6%
C: 5.4%
piter-02 positive trial results
Phase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus
Published: 2023-05-31 (Crawled : 09:00) - biospace.com/
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.13%
H: 1.53%
C: 0.98%
rinvoq lupus therapy study
New England Journal of Medicine Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Crohn's Disease
Published: 2023-05-25 (Crawled : 17:00) - biospace.com/
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.79%
H: 0.12%
C: -1.01%
rinvoq disease results
DelveInsight Evaluates a Robust Dry Eye Disease Clinical Trial Pipeline as 60+ Influential Pharma Players to Set Foot in the Domain
Published: 2023-05-23 (Crawled : 15:00) - prnewswire.com
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: -1.22%
H: 0.0%
C: -0.62%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: -1.22%
GKOS | $100.93 -0.17% 0.0% 520K
|
Health Technology
|
| O: -0.71%
H: 2.06%
C: -1.05%
BHC | $8.56 0.35% 0.0% 2M
|
Health Technology
|
| O: -2.27%
H: 4.24%
C: -2.21%
ALC | $79.57 -1.47% 0.0% 850K
|
Health Technology
|
| O: -0.51%
H: 0.02%
C: -3.25%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.31%
H: 0.26%
C: -1.34%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: 0.0%
OCUL | News | $4.645 -7.1% -7.64% 3.9M
|
Health Technology
|
| O: 4.45%
H: 7.65%
C: 2.21%
GRFS | $6.4 -1.23% -1.25% 960K
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: -3.74%
ALDX | $3.93 0.51% 0.51% 570K
|
Health Technology
|
| O: 0.0%
H: 2.36%
C: 0.61%
pharma disease pipeline set eye trial
Plus Therapeutics Expands Collaboration with Piramal Pharma Solutions to Meet Increase in Investigational Drug Demand for Ongoing and Planned Clinical Trials
Published: 2023-05-02 (Crawled : 11:00) - globenewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.1%
H: 0.96%
C: -1.26%
PSTV | News | $1.55 -4.91% -5.16% 8.4K
|
Health Technology
|
| O: 2.01%
H: 0.0%
C: -9.09%
pharma drug ongoing trials solutions collaboration therapeutics plus
AbbVie Announces Late-Breaking Results from Phase 3 Trial Evaluating Atogepant (QULIPTA®) for the Preventive Treatment of Episodic Migraine Among Patients with Prior Treatment Failure at the 2023 AAN Annual Meeting
Published: 2023-04-21 (Crawled : 05:00) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.53%
H: 0.37%
C: -0.11%
qulipta abbvie treatment meeting trial migraine results
AbbVie Clinches Back-to-Back Clinical Wins in Ulcerative Colitis, Lupus
Published: 2023-03-24 (Crawled : 13:00) - biospace.com/
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.01%
H: 2.06%
C: 1.76%
abbvie lupus ulcerative colitis
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.